Interstitial Lung Disease in Rheumatoid Arthritis
- 14 July 2010
- journal article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 12 (5) , 363-369
Abstract
Rheumatoid arthritis (RA) is the most common systemic autoimmune disease in the United States, affecting 1% to 2% of the adult population. Although joints and synovium are the primary targets in this disorder, extra-articular manifestations involving the lungs can lead to significant morbidity and excess mortality. Among the various pulmonary complications that occur in RA, interstitial lung disease (ILD) is the most damaging, with effects ranging from subclinical inflammation/scarring to end-stage pulmonary fibrosis. New insights during the past several years have underscored the epidemiologic impact of clinically/functionally significant RA-associated ILD (RA-ILD) and have begun to identify factors contributing to the pathogenesis of this potentially devastating complication of RA. Despite these advancements, the complexity of RA-ILD and the lack of reliable predictors for disease progression highlight the need for improved biomarker development. Establishing such detailed molecular signatures will ultimately guide the application and timing of therapeutic agents that include immunomodulators as well as newly studied antifibrotic agents.Keywords
This publication has 47 references indexed in Scilit:
- Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population‐based studyArthritis & Rheumatism, 2010
- Rheumatoid Arthritis-Associated Interstitial Lung DiseaseChest, 2009
- Pulmonary fibrosis: pathogenesis, etiology and regulationMucosal Immunology, 2009
- Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cellsAnnals of the Rheumatic Diseases, 2008
- MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary FibrosisPLOS Medicine, 2008
- The Role of Inflammation in the Pathogenesis of Idiopathic Pulmonary FibrosisAntioxidants & Redox Signaling, 2008
- Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritisClinical Rheumatology, 2008
- Roger S. Mitchell Lecture. Rheumatoid Lung DiseaseProceedings of the American Thoracic Society, 2007
- Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptomsClinical Rheumatology, 2006
- Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary FibrosisPLOS Medicine, 2005